Vol 3, No 2 (2017)
Review paper
Published online: 2017-06-20
Strategia leczenia chorych na reumatoidalne zapalenie stawów z uwzględnieniem obecności czynników „złej prognozy”
Forum Reumatol 2017;3(2):57-64.
Abstract
Reumatoidalne zapalenie stawów (RZS), to autoimmunologiczna przewlekła choroba zapalna o nie do końca poznanej etiologii, z możliwością ograniczenia funkcjonowania, występowaniem zmian pozastawowych i objawów układowych, może doprowadzić do niszczenia i deformacji stawów, niepełnosprawności. Budując strategię postępowania u chorego na RZS, należy znać punkty istotne strategicznie - czynniki prognostyczne, zwłaszcza te niekorzystne dla chorego. Pozwalają one określić „profil” chorego, czyli wybrać, u której osoby z dużym prawdopodobieństwem, choroba będzie przebiegać bardziej agresywnie, szybciej dojdzie do zniszczenia/deformacji, ograniczeń w funkcjonowaniu. Informacje te są przydatne w podejmowaniu optymalnych decyzji terapeutycznych. Kluczową zasadą w ustalaniu strategii postępowania z chorym na RZS powinna być współpraca i zaufanie pomiędzy lekarzem a pacjentem, gdyż tylko zalecona i odpowiednio stosowana przez chorego terapia pozwala osiągnąć satysfakcjonujący cel leczenia.
Keywords: reumatoidalne zapalenie stawów (RZS)czynniki prognostycznestrategia leczenia
References
- Villarino MR, Moreno JR. Are Prognostic Factors Useful in Rheumatoid Arthritis? Reumatología Clínica (English Edition). 2011; 7(5): 339–342.
- Spector TD. Rheumatoid arthritis. Rheum Dis Clin North Am. 1990; 16: 513–37.
- Mau W, Bornmann M, Weber H, et al. Prediction of permanent work disability in a follow-up study of early rheumatoid arthritis: results of a tree structured analysis using RECPAM. Mau Semin Arthritis Rheum. 1991; 21: 4–12.
- Graell E, Vazquez I, Larrosa M, et al. Disability measured by the modified health assessment questionnaire in early rheumatoid arthritis: prognostic factors after two years of follow-up. Clin Exp Rheumatol. 2009; 27(2): 284–291.
- Sanmarti R, Gomez A, Ercilla G, et al. Radiological progression in early rheumatoid arthritis after DMARDS: a one-year follow-up study in a clinical setting. Rheumatology (Oxford). 2003; 42(9): 1044–1049.
- Lindqvist E, Eberhardt K, Bendtzen K, et al. Prognostic laboratory markers of joint damage in rheumatoid arthritis. Ann Rheum Dis. 2005; 64(2): 196–201.
- Hetland ML, Stengaard-Pedersen K, Junker P, et al. CIMESTRA study group. Radiographic progression and remission rates in early rheumatoid arthritis - MRI bone oedema and anti-CCP predicted radiographic progression in the 5-year extension of the double-blind randomised CIMESTRA trial. Ann Rheum Dis. 2010; 69(10): 1789–1795.
- van der Heijde D, Klareskog L, Singh A, et al. Patient reported outcomes in a trial of combination therapy with etanercept and methotrexate for rheumatoid arthritis: the TEMPO trial. Ann Rheum Dis. 2006; 65(3): 328–334.
- Burmester GR, Ferraccioli G, Flipo RM, et al. Clinical remission and/or minimal disease activity in patients receiving adalimumab treatment in a multinational, open-label, twelve-week study. Arthritis Rheum. 2008; 59(1): 32–41.
- Mancarella L, Bobbio-Pallavicini F, Ceccarelli F, et al. GISEA group. Good clinical response, remission, and predictors of remission in rheumatoid arthritis patients treated with tumor necrosis factor-alpha blockers: the GISEA study. J Rheumatol. 2007; 34(8): 1670–1673.
- Pease CT, Bhakta BB, Devlin J, et al. Does the age of onset of rheumatoid arthritis influence phenotype?: a prospective study of outcome and prognostic factors. Rheumatology (Oxford). 1999; 38(3): 228–234.
- Forslind K, Hafström I, Ahlmén M, et al. BARFOT Study Group. Sex: a major predictor of remission in early rheumatoid arthritis? Ann Rheum Dis. 2007; 66(1): 46–52.
- Gossec L, Dougados M, Goupille P, et al. Prognostic factors for remission in early rheumatoid arthritis: a multiparameter prospective study. Ann Rheum Dis. 2004; 63(6): 675–680.
- Radovits BJ, Fransen J, Al Shamma S, et al. Excess mortality emerges after 10 years in an inception cohort of early rheumatoid arthritis. Arthritis Care Res (Hoboken). 2010; 62(3): 362–370.
- Pincus T, Callahan LF, Burkhauser RV. Most chronic diseases are reported more frequently by individuals with fewer than 12 years of formal education in the age 18-64 United States population. J Chronic Dis. 1987; 40(9): 865–874.
- Ang DC, Choi H, Kroenke K, et al. Comorbid depression is an independent risk factor for mortality in patients with rheumatoid arthritis. J Rheumatol. 2005; 32(6): 1013–1019.
- Ramiro S, Sepriano A, Chatzidionysiou K, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis. 2017; 76(6): 960–977.
- Feldman DE, Bernatsky S, Houde M, et al. Early consultation with a rheumatologist for RA: does it reduce subsequent use of orthopaedic surgery? Rheumatology (Oxford). 2013; 52(3): 452–459.
- Felson DT, Smolen JS, Wells G, et al. American College of Rheumatology, European League Against Rheumatism. American College of Rheumatology/European League against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Ann Rheum Dis. 2011; 70(3): 404–413.
- Ranganath VK, Motamedi K, Haavardsholm EA, et al. Comprehensive appraisal of magnetic resonance imaging findings in sustained rheumatoid arthritis remission: a substudy. Arthritis Care Res (Hoboken). 2015; 67(7): 929–939.
- Sakellariou G, Scirè CA, Verstappen SMM, et al. In patients with early rheumatoid arthritis, the new ACR/EULAR definition of remission identifies patients with persistent absence of functional disability and suppression of ultrasonographic synovitis. Ann Rheum Dis. 2013; 72(2): 245–249.
- Aletaha D, Alasti F, Smolen JS. Optimisation of a treat-to-target approach in rheumatoid arthritis: strategies for the 3-month time point. Ann Rheum Dis. 2016; 75(8): 1479–1485.
- Schipper LG, Fransen J, den Broeder AA, et al. Time to achieve remission determines time to be in remission. Arthritis Res Ther. 2010; 12(3): R97.
- Atsumi T, Yamamoto K, Takeuchi T, et al. The first double-blind, randomised, parallel-group certolizumab pegol study in methotrexate-naive early rheumatoid arthritis patients with poor prognostic factors, C-OPERA, shows inhibition of radiographic progression. Ann Rheum Dis. 2016; 75(1): 75–83.
- Vollenhoven Rv, Geborek P, Forslind K, et al. Conventional combination treatment versus biological treatment in methotrexate-refractory early rheumatoid arthritis: 2 year follow-up of the randomised, non-blinded, parallel-group Swefot trial. The Lancet. 2012; 379(9827): 1712–1720.
- Visser K, Goekoop-Ruiterman YPM, de Vries-Bouwstra JK, et al. A matrix risk model for the prediction of rapid radiographic progression in patients with rheumatoid arthritis receiving different dynamic treatment strategies: post hoc analyses from the BeSt study. Ann Rheum Dis. 2010; 69(7): 1333–1337.
- Lee E, Fleischmann R, Hall S, et al. Radiographic, clinical and functional comparison of tofacitinib monotherapy versus methotrexate in methotrexate-nave patients with rheumatoid arthritis. Arthritis Rheum. 2012; 64: S1049.
- Jones G, Sebba A, Gu J, et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann Rheum Dis. 2010; 69(1): 88–96.
- Smolen JS, Burmester GR, Combe B, et al. Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE study. Lancet. 2016; 388(10061): 2763–2774.
- Emery P, Hammoudeh M, FitzGerald O, et al. FRI0089 Assessing maintenance of remission with reduced dose etanercept plus methotrexate, methotrexate alone, or placebo in patients with early rheumatoid arthritis who achieved remission with etanercept and methotrextate: the prize study. Annals of the Rheumatic Diseases. 2014; 72(Suppl 3): A399.2–A399.
